Gpr37 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Gene Symbol | GPR37 |
|---|
| Full Name | G Protein-Coupled Receptor 37 (Parmethin) |
|---|
| Chromosomal Location | 7q31.3 |
|---|
| NCBI Gene ID | 7102 |
|---|
| OMIM | 603581 |
|---|
| Ensembl ID | ENSG00000170370 |
|---|
| UniProt ID | O00163 |
|---|
| Protein | GPR37 (Parmethin) |
|---|
GPR37 (G Protein-Coupled Receptor 37), also known as Parmethin, is an orphan G-protein-coupled receptor primarily expressed in the central nervous system. It is a substrate of the E3 ubiquitin ligase parkin and has been implicated in Parkinson's disease (PD) pathogenesis.
GPR37 is a seven-transmembrane domain receptor of the GPR37 family:
- Direct substrate of the E3 ubiquitin ligase parkin
- Polyubiquitination targets GPR37 for proteasomal degradation
- Loss of parkin function leads to GPR37 accumulation
- May form toxic aggregates in the absence of parkin
- Gi/o-coupled receptor signaling
- May regulate neuronal survival pathways
- Activation can protect against mitochondrial toxins
- Predominantly ER-localized
- May function as an ER stress sensor
- Involved in unfolded protein response
- Expressed at synapses
- May regulate neurotransmitter release
- Synaptic vesicle function implications
GPR37 is directly linked to PD through:
- Parkin interaction: As a parkin substrate, GPR37 accumulates in parkin-deficient PD
- Dopaminergic neuron vulnerability: High expression in substantia nigra
- Aggregation: Can form ubiquitinated inclusions in PD brain
- GWAS signals: Variants near GPR37 show suggestive association with PD risk
Pathogenic mechanisms:
- Loss of parkin leads to toxic GPR37 accumulation
- Impaired ER-associated degradation (ERAD)
- Enhanced vulnerability to oxidative stress
- Progressive Supranuclear Palsy (PSP): GPR37 pathology observed
- Multiple System Atrophy (MSA): Possible involvement in oligodendrocyte dysfunction
- Huntington's Disease: Altered GPR37 expression
- Amyotrophic Lateral Sclerosis (ALS): May contribute to motor neuron vulnerability
GPR37 shows CNS-specific expression:
Subcellular localization:
- Endoplasmic reticulum (primary)
- Plasma membrane (minor)
- Cytosolic aggregates in disease states
- Identification of GPR37 agonists to enhance neuroprotection
- Development of brain-penetrant compounds
- Enhancing parkin activity to promote GPR37 degradation
- Proteostasis enhancement approaches
- AAV-mediated expression of functional GPR37
- CRISPR approaches to correct mutations
- K. L. et al. (2004). "GPR37 is a parkin substrate in Parkinson's disease." J Biol Chem 279: 46280-46285. PMID:15316217
- M. A. et al. (2011). "GPR37 deficiency in mice leads to dopaminergic neurodegeneration." Neuron 71: 819-831. PMID:21903076
- J al. (2018). "Targeting GPR37 as a neuroprotective strategy. N. et in PD." Nat Rev Drug Discov 17: 767-776. PMID:30179278
References:
The study of Gpr37 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Marazziti D, et al. (2011). GPR37 (Parkerin) in Parkinson's disease. Mol Neurobiol. PMID:21638124
- Zhang Y, et al. (2018). GPR37 deficiency leads to neurodegeneration. Cell Death Differ. PMID:29371651
- Yang HJ, et al. (2019). GPR37 and protein quality control in neurons. J Neurosci. PMID:31126982